The value of erythropoietin therapy in cancer patients

American Journal of Cancer

Volumn 4, Issue 2, 2005, Pages 87-103

  Booton, Richard ^a   Thatcher, Nick ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG USE; FATIGUE; HUMAN; MAINTENANCE DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TRANSFUSION;

EID: 22244435270     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200504020-00003     Document Type: Review

References (111)

1. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey: The Fatigue Coalition. Semin Hematol 1997; 34 (3 Suppl. 2): 4-12
2. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5 (5): 353-60
3. Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol 2000; 1: 138-47
4. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92 (6 Suppl.): 1684-8
5. Atkinson A, Barsevick A, Cella D, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Huntingt) 2000; 14 (11A): 151-61
6. Stone P. The measurement, causes and effective management of cancer-related fatigue. Int J Palliat Nurs 2002; 8 (3): 120-8
7. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28 (2 Suppl. 8): 7-14
8. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13 (2): 63-74
9. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25 (3 Suppl. 7): 43-6
10. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94 (2): 528-38
11. Singer JD, Granahan P, Goodrich NN, et al. Diet and iron status, a study of relationships: United States 1971-74. Vital and health statistics. Washington, DC: National Centre for Health Statisitics, 1982. Series 11 no. 229
12. Surgenor D, Wallace E, Hao S, et al. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med 1990; 322 (23): 1646-51
13. Denton TA, Diamond GA, Matloff JM, et al. Anemia therapy: individual benefit and societal cost. Semin Oncol 1994; 21 (2 Suppl. 3): 29-35
14. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 1997; 15 (3): 1218-34
15. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study: Procrit Study Group. J Clin Oncol 1998; 16 (10): 3412-25
16. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19 (11): 2865-74
17. Cleeland C, Demetri G, Glaspy J, et al. Identifying haemoglobin level for optimal hemogloquality of life: results of an incremental analysis [abstract 2215]. Proc Am Soc Clin Oncol 1999; 18: 574a
18. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001; 28 (2 Suppl. 8): 19-23
19. Kling PJ, Dragsten PR, Roberts RA, et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 1996; 95 (2): 241-8
20. Weiss G, Houston T, Kastner S, et al. Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells. Blood 1997; 89 (2): 680-7
21. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21 (2 Suppl. 3): 3-8
22. Cox R, Musial T, Gyde OH. Reduced erythropoietin levels as a cause of anaemia in patients with lung cancer. Eur J Cancer Clin Oncol 1986; 22 (4): 511-4
23. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in chemopatients with the anemia of cancer. N Engl J Med 1990; 322 (24): 1689-92
24. Joosten E, Van Hove L, Lesaffre E, et al. Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia. J Am Geriatr Soc 1993; 41 (12): 1301-4
25. Ozguroglu M, Arun B, Demir G, et al. Serum erythropoietin level in anemic cancer patients. Med Oncol 2000; 17 (1): 29-34
26. Braczkowski R, Romanawsky W, Danikiewicz A, et al. Decrease of erythropoietin level by human recombinant tumour necrosis factor alpha (hrec TNFalpha) in patients with advanced cancer. J Biol Regul Homeost Agents 2001; 15 (4): 366- 9
27. Beguin Y, Yerna M, Loo M, et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82 (4): 648-53
28. Dowlati A, R'Zik S, Fillet G, et al. Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol 1997; 97 (2): 297-9
29. Cazzola M. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Med Oncol 2000; 17 Suppl. 1: S11-16
30. Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18 (2): 109-13
31. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer 1991; 68 (5): 1101-5
32. Gamucci T, Thorel MF, Frasca AM, et al. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A Suppl. 2: S13-14
33. Onat H, Inanc SE, Dalay N, et al. Effect of cisplatin on erythropoietin and iron changes [letter]. Eur J Cancer 1993; 29A (5): 777
34. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95 (4): 1650-9
35. Ludwig H, Leitgeb C, Fritz E, et al. Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer 1993; 29A Suppl. 2: S8-12
36. Leitgeb C, Pecherstorfer M, Fritz E, et al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73 (10): 2535-42
37. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76 (11): 2319-29
38. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19 (21): 4126-34
39. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A Suppl. 2: S2-8
40. Glimelius B, Linne T, Hoffman K, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998; 16 (2): 434- 40
41. Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma: a prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995; 155 (19): 2069-74
42. Johansson JE, Wersall P, Brandberg Y, et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer: a randomized study. Scand J Urol Nephrol 2001; 35 (4): 288-94
43. Daneryd P, Svanberg E, Korner U, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 1998; 58 (23): 5374-9
44. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91 (19): 1616-34
45. Skillings JR, Sridhar FG, Wong C, et al. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol 1993; 16 (1): 22-5
46. Barrett-Lee PJ, Bailey NP, O'Brien ME, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemopatients therapy. Br J Cancer 2000; 82 (1): 93-7
47. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21 (2): 105-13
48. Coebergh JW, Janssen-Heijnen ML, Post PN, et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 1999; 52 (12): 1131-6
49. Del Mastro L, Venturini M. Strategies for the use of epoetin alfa in breast cancer patients. Oncologist 1998; 3 (5): 314-8
50. Del Mastro L, Venturini M, Lionetto R, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15 (7): 2715-21
51. Dunphy FR, Harrison BR, Dunleavy TL, et al. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86 (7): 1362-7
52. Levine EA, Laborde C, Hambrick E, et al. Influence of erythropoietin on transfu-sion requirements in patients receiving preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum 1999; 42 (8): 1065-9
53. Dunphy FR, Dunleavy TL, Harrison BR, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79 (8): 1623-8
54. Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80 (3-4): 396- 402
55. de Campos E, Radford J, Steward W, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995; 13 (7): 1623-31
56. Welch RS, James RD, Wilkinson PM, et al. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer [abstract]. Cancer J Sci Am 1995; 1 (4): 261
57. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15 (3): 174-82
58. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21 (2 Suppl. 3): 21-8
59. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20 (10): 2486-94
60. Kurz C, Marth C, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65 (3): 461-6
61. Wurnig C, Windhager R, Schwameis E, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36 (2): 155-9
62. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19 (11): 2875-82
63. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9 (3): 255-60
64. Nguyen TV, Trinh GN. Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation [letter]. J Clin Oncol 2002; 20 (3): 878
65. Gabrilove J, Sarokhan B, Cremieux P. Statistical explanations for a community-based study of once-weekly epoetin alpha therapy in patients receiving chemotherapy. J Clin Oncol 2002; 20 (11): 2757
66. Ray-Coquard I, Le Cesne A, Rubio MT, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens: the Elypse 1 Study Group. J Clin Oncol 1999; 17 (9): 2840-6
67. Pivot X, Guardiola E, Etienne M, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000; 36 (7): 852-7
68. Urabe A, Mizoguchi H, Takaku F, et al. Phase II clinical study of recombinant human erythropoietin on the anemia associated with multiple myeloma [in Japanese]. Rinsho Ketsueki 1993; 34 (8): 919-27
69. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86 (12): 4446-53
70. Henry DH, Brooks Jr BJ, Case Jr DC, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy [abstract]. Cancer J Sci Am 1995; 1 (4): 252
71. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81 (5): 434-41
72. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84 (4): 1056-63
73. Henry D, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood 1995; 85 (6): 1676-8
74. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28 (2 Suppl. 8): 29-35
75. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28 (2 Suppl. 8): 36-41
76. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93 (4): 266-76
77. Hall E. The oxygen effect and reoxygenation. In: Hall EJ, editor. Radiobiology for the radiologist. 5th ed. Philadelphia (PA): JB Lippincott Co., 1994: 91-111
78. Okunieff P, de Bie J, Dunphy EP, et al. Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. Br J Cancer Suppl 1996; 27: S185-190
79. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy: the Freiburg experience. Strahlenther Onkol 1998; 174 Suppl. 4: 31-4
80. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001; 28 (2 Suppl. 8): 60-5
81. Obermair A, Cheuk R, Horwood K, et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 2001; 92 (4): 903-8
82. Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlenther Onkol 1998; 174 Suppl. 4: 20-3
83. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998; 77 (11): 1996-2002
84. Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994; 29 (5): 1079-84
85. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27 (5): 1147-52
86. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50 (3): 705-15
87. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 Suppl. 1: 3-10
88. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40 (1): 110-8
89. Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62 (6): 2167-75
90. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001; 84 Suppl. 1: 11-6
91. Glaspy J, Colowick A, Heatherington A. Novel erythropoiesis stimulating protein exhibits a prolonged serum half life in oncology patients [abstract 210] [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002640-00_18- 002-00_19-00202478,00.asp [Accessed 2005 Apr 22]
92. Smith R, Tchekmedyian S, Richards D, et al. Darbepoetin alfa effectively alleviates anaemia in patients with the chronic anaemia of cancer: efficacy and pharmacokinetic results of a dose escalation study [abstract 1465] [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002640-00_18-0016-00_19- 001465,00.asp [Accessed 2005 Apr 22]
93. Smith Jr RE, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001; 84 Suppl. 1: 24-30
94. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87 (3): 268-76
95. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84 Suppl. 1: 17- 23
96. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002; 119 (1): 79-86
97. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94 (16): 1211-20
98. Heatherington A, Rovetti R, Kotasek D, et al. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with non-myeloid malignancie receiving cyclic chemotherapy [abstract 471] [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002640-00_18- 0010-00_19-00471,00.asp [Accessed 2005 Apr 22]
99. Kotasek D, Albertsson M, Mackey J, et al. Randomised double blind placebo controlled dose finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumours [abstract 1421] [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002640-00_18-0010-00_19- 001569,00.asp [Accessed 2005 Apr 22]
100. Glaspy J, Jadeja J, Justice G, et al. Optimizing the management of anaemia in patients with cancer: a randomised active controlled study investigating the dosing of darbepoetin alfa [abstract 1446] [online]. Available from URL: http:// www.asco.org/ac/1,1003,_12-002640-00_18-0016-00_19-001446,00. asp [Ac- cessed 2005 Apr 22]
101. Kallich J, Erder H, Glaspy J, et al. Darbepoetin alfa has higher observed improvements in fatigue and physical well being than epoetin alfa [abstract 1466] [online]. Available from URL: http://www.asco.org/ac/1,1003,_12-002640- 00_18-0016-00_19-001466,00.asp [Accessed 2005 Apr 22]
102. Bottomley A, Thomas R, van Steen SK, et al. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 2002; 3 (3): 145-53
103. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? a cost-benefit analysis. Cancer 1998; 83 (12): 2588-96
104. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78 (6): 781-7
105. Kavanagh BD, Fischer BAT, Segreti EM, et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51 (2): 435-41
106. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78 (6): 781-7
107. Martin SC, Gagnon DD, Zhang L, et al. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003; 21 (16): 1153-69
108. Cremieux PY, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999; 16 (5 Pt 1): 459-72
109. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? a cost-benefit analysis. Cancer 1998; 83 (12): 2588-96
110. Sheffield R, Sullivan SD, Saltiel E, et al. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31 (1): 15-22
111. Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004; 22 (16): 1029-45